All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2025-06-09.
From the record
Lineage Cell Therapeutics, Inc.'s filings since 2017 show 3 warning events: an auditor change (8-K item 4.01, 3 times, the latest 2025-06-09) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+10.6% a year over 10 filed years; profitable in 1 of 10.
From the record
Lineage Cell Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $4 million in fiscal 2012 to $15 million in fiscal 2025, up 10.6% a year; it rose in 7 of 9 years; the deepest fall was 74% from fiscal 2015 to fiscal 2020; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Lineage Cell Therapeutics, Inc.'s shareholder treatment is put at 6.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 32% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -147%: lost 147¢ per shareholder dollar. Leverage 61%: owes 61¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Lineage Cell Therapeutics, Inc. lost about 147 cents for every dollar of shareholders' money. Leverage: it owed about 61 cents per dollar of assets, and net share issuance: its share count grew 14.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 42% of 102 in its family; net margin -436.5%.
From the record
Lineage Cell Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $15 million in fiscal 2025 ranks in the bottom 42% by size; a net margin of -436.5% ranks in the bottom 43%; revenue growth of -0.3% a year over the last 3 filed years ranks in the bottom 41% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 11% of 110 in its family for leadership; chief executive since 2018.
From the record
Lineage Cell Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Culley, Brian M (President and CEO, as filed), filing under that title since 2018-09-19, 8.2 years (top 17% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 8.2 years (top 9%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 48% of 92 in its family for room to expand.
From the record
Lineage Cell Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $41 million against no long-term debt tagged leaves 36.2% of its assets as net cash, top 42% of its family; cash from operations less capital spending is -133.6% of revenue (top 44%); research spending of 121.8% of revenue (bottom 42%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 37% of 100 in its family for growth drivers.
From the record
Lineage Cell Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.3% a year over the last three filed years against 10.6% over all 10, slowing (bottom 46% of its family); the newest year grew 53.3% (top 35%); research spending grew 8.2% a year (top 37%); capital spending grew 8.1% a year (top 23%) (its annual reports). Lineage Cell Therapeutics, Inc. reported 2 product lines in fiscal 2025: Collaboration Revenues at $14 million (94%), Royalties License and Other Revenues at $947 thousand (7%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 36% of 72 in its family for expectations against reality.
From the record
Lineage Cell Therapeutics, Inc.'s newest year against its own record: revenue of $15 million in fiscal 2025 came in 90.6% above the $8 million its prior three years' pace pointed to (top 20% of its family); net income of $64 million against a prior three-year average of $22 million (bottom 9%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 20%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made